Published in Nat Med on August 01, 1997
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J (1997) 4.66
A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A (2004) 3.95
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Characterization of XIAP-deficient mice. Mol Cell Biol (2001) 3.32
Mechanisms of apoptosis. Am J Pathol (2000) 3.23
Induction of apoptosis by Drosophila reaper, hid and grim through inhibition of IAP function. EMBO J (2000) 3.02
The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol (2012) 2.99
Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma (2004) 2.94
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A (2006) 2.86
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol (1998) 2.64
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest (2004) 2.59
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut (2000) 2.56
HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J (2003) 2.47
Cytokinesis in eukaryotes. Microbiol Mol Biol Rev (2002) 2.43
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck (2008) 2.28
Human survivin is a kinetochore-associated passenger protein. J Cell Biol (2000) 2.21
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol (2011) 2.09
Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest (2001) 2.05
The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med (1999) 1.98
Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A (2001) 1.89
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med (2003) 1.83
Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med (2004) 1.80
Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A (2004) 1.79
Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol (2008) 1.79
Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol (2001) 1.78
Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc Natl Acad Sci U S A (1999) 1.77
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 1.73
CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem (2008) 1.71
A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J Cell Biol (1998) 1.68
The Survivin saga goes in vivo. J Clin Invest (2001) 1.66
A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest (2001) 1.64
Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer (2002) 1.62
Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med (2012) 1.61
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Inhibitor of apoptosis proteins physically interact with and block apoptosis induced by Drosophila proteins HID and GRIM. Mol Cell Biol (1998) 1.60
Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J (2002) 1.57
Retracted Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) (2009) 1.57
Prognostic importance of survivin in breast cancer. Br J Cancer (2003) 1.56
Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest (2005) 1.55
Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line. J Cell Biol (2008) 1.54
Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med (2007) 1.52
Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A (1999) 1.52
IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol (2002) 1.51
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res (2012) 1.48
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis (2009) 1.46
Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer (2002) 1.45
Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A (2005) 1.43
Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia (2000) 1.42
Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol (1998) 1.41
Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem (2001) 1.41
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40
Sterilizing immunity in the lung relies on targeting fungal apoptosis-like programmed cell death. Science (2017) 1.40
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol (2009) 1.39
Receptor-mediated choreography of life and death. J Clin Immunol (2003) 1.33
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell (2006) 1.33
Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer (2003) 1.33
Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology (2009) 1.31
Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. J Neurosci (2008) 1.31
Apoptosis: targets in pancreatic cancer. Mol Cancer (2003) 1.31
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest (2010) 1.30
Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin. Stem Cells (2007) 1.30
Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer (2006) 1.29
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol (2003) 1.29
Role of the Survivin gene in pathophysiology. Am J Pathol (2006) 1.28
Survivin as a preferential target for cancer therapy. Int J Mol Sci (2014) 1.28
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol (2000) 1.27
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol (2001) 1.27
Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer (2009) 1.27
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer (2011) 1.26
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer (2005) 1.26
DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer (2015) 1.25
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer (2003) 1.24
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn (2010) 1.23
Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A (2013) 1.22
Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med (2004) 1.22
Inhibitor of apoptosis proteins in eukaryotic evolution and development: a model of thematic conservation. Dev Cell (2008) 1.21
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood (2009) 1.21
Suppressors of Bir1p (Survivin) identify roles for the chromosomal passenger protein Pic1p (INCENP) and the replication initiation factor Psf2p in chromosome segregation. Mol Cell Biol (2005) 1.20
Reovirus-induced apoptosis requires mitochondrial release of Smac/DIABLO and involves reduction of cellular inhibitor of apoptosis protein levels. J Virol (2002) 1.18
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med (2004) 1.17
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol (2009) 1.17
Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A (2011) 1.16
Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A (2004) 1.16
Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J R Soc Interface (2010) 1.16
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem (2010) 1.16
NF-kappaB determines localization and features of cell death in epidermis. J Clin Invest (2000) 1.15
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol (1999) 4.11
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol (1998) 2.64
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res (1998) 2.38
Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem (1998) 2.27
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell (1993) 2.22
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest (2001) 2.05
Myeloid sarcoma: clinical and morphologic criteria useful for diagnosis. Int J Surg Pathol (2003) 1.95
The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res (1999) 1.89
Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A (2001) 1.89
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87
Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem (1999) 1.82
Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell (2000) 1.70
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest (2001) 1.64
Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest (1997) 1.61
Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene (2006) 1.59
Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med (1999) 1.58
Cytokine-regulated expression of survivin in myeloid leukemia. Blood (2001) 1.56
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol (2000) 1.56
Endothelial cell activation by leukocyte microparticles. J Immunol (1998) 1.49
Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci U S A (1993) 1.45
In vivo immunosuppression by targeting a novel protease receptor. Nature (1996) 1.42
Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc Natl Acad Sci U S A (1995) 1.39
Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev (2001) 1.36
Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest (1999) 1.31
Cell division regulation by BIR1, a member of the inhibitor of apoptosis family in yeast. J Biol Chem (2000) 1.29
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol (2001) 1.27
Urine detection of survivin and diagnosis of bladder cancer. JAMA (2001) 1.23
Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem (1997) 1.23
Binding of fibrinogen to human monocytes. J Clin Invest (1986) 1.20
A functional analysis of a natural variant of intercellular adhesion molecule-1 (ICAM-1Kilifi). Hum Mol Genet (2000) 1.19
Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain. J Biol Chem (1994) 1.18
Survivin does not inhibit caspase-3 activity. Blood (2000) 1.15
Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest (2001) 1.13
Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res (2003) 1.13
Survivin expression in oral squamous cell carcinoma. Br J Cancer (2003) 1.06
Apical topography and modulation of ICAM-1 expression on activated endothelium. Am J Pathol (1995) 1.05
Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells. Kidney Int (1991) 1.04
Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem (1996) 0.99
Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem (1997) 0.99
High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem (1994) 0.97
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br J Cancer (2011) 0.97
miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene (2011) 0.96
A peptide derived from the intercellular adhesion molecule-2 regulates the avidity of the leukocyte integrins CD11b/CD18 and CD11c/CD18. J Cell Biol (1995) 0.96
The vascular E-selectin binds to the leukocyte integrins CD11/CD18. Glycobiology (1993) 0.94
Caspase 2-mediated tumor suppression involves survivin gene silencing. Oncogene (2009) 0.94
Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem (1997) 0.93
Fibrinogen mediates leukocyte-endothelium bridging in vivo at low shear forces. Blood (1996) 0.93
Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol (2001) 0.93
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene (2009) 0.92
Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis. Pathol Res Pract (2003) 0.90
Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant (1992) 0.90
Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A (1998) 0.88
Dual regulation of ligand binding by CD11b I domain. Inhibition of intercellular adhesion and monocyte procoagulant activity by a factor X-derived peptide. J Biol Chem (1998) 0.88
Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J (1996) 0.88
Induction of MHC class II molecules HLA-DR, -DP and -DQ and ICAM 1 in human podocytes by gamma-interferon. Exp Nephrol (1995) 0.87
Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. Hum Mol Genet (1998) 0.84
Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem (1996) 0.84
Species-specific properties of the glomerular mesangium. J Am Soc Nephrol (1993) 0.83
Cytokinesis, apoptosis and survivin: three for tango? Cell Death Differ (2001) 0.83
Thromboxane generation by human monocytes enhances platelet function. J Exp Med (1986) 0.81
Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. J Biol Chem (1998) 0.77
AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive. J Leukoc Biol (2000) 0.77
Tumor necrosis factor alpha increases antifibrinolytic activity of cultured human mesangial cells. Kidney Int (1992) 0.77
Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells. Am J Pathol (1992) 0.77
[Role of hemostasis in the formation of crescents in extracapillary glomerulonephritis]. Nephrologie (1992) 0.77
Thrombin signal transduction mechanisms in human glomerular epithelial cells. J Cell Physiol (1992) 0.77
von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol (1986) 0.76
High affinity cross-reacting mAb generated by minimal mimicry: implications for the pathogenesis of anti-nuclear autoantibodies and immunosuppression. Proc Natl Acad Sci U S A (1998) 0.75
Rapid assay of phage-derived recombinant human fabs as bispecific antibodies. Biotechnology (N Y) (1995) 0.75
Transcriptional activation of the urokinase receptor gene by endothelin-1. Biochem Biophys Res Commun (1992) 0.75
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Blood (1996) 0.75